These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39117370)

  • 21. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.
    Ma N; Bansal M; Chu J; Branch AD
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):229-237. PubMed ID: 38693784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes.
    Chen YT; Chen TI; Yang TH; Yin SC; Lu SN; Liu XR; Gao YZ; Lin CJ; Huang CW; Huang JF; Yeh ML; Huang CF; Dai CY; Chuang WL; Yang HI; Yu ML; Lee MH
    Am J Gastroenterol; 2024 Apr; ():. PubMed ID: 38534155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
    J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
    Han E; Lee BW; Kang ES; Cha BS; Ahn SH; Lee YH; Kim SU
    Metabolism; 2024 Mar; 152():155789. PubMed ID: 38224909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes.
    Michel M; Doll M; Albert N; Morgenstern M; Behr A; Maxeiner S; Labenz C; Galle PR; Schattenberg JM
    United European Gastroenterol J; 2024 Feb; 12(1):11-21. PubMed ID: 38206118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease.
    Roy A; De A; Kulkarni AV; Jajodia S; Goenka U; Tewari A; Sonthalia N; Goenka MK
    J Obes Metab Syndr; 2024 Sep; 33(3):222-228. PubMed ID: 39098054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1382-1393. PubMed ID: 38629681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study.
    Kim K; Lee Y; Lee JS; Kim MN; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Jung I; Lee HW
    J Gastroenterol Hepatol; 2024 Sep; ():. PubMed ID: 39343427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
    Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD
    Hepatology; 2024 May; ():. PubMed ID: 38739848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study.
    Park Y; Jung J; Han S; Kim GA
    Aliment Pharmacol Ther; 2024 Sep; ():. PubMed ID: 39304991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals.
    Martínez-Domínguez SJ; García-Mateo S; Gargallo-Puyuelo CJ; Gallego-Llera B; Callau P; Mendi C; Arroyo-Villarino MT; Simón-Marco MÁ; Ampuero J; Gomollón F
    Inflamm Bowel Dis; 2024 Aug; 30(8):1274-1283. PubMed ID: 37607330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
    Perumpail BJ; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A; Kim D
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):110-118. PubMed ID: 38623942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
    Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and molecular characterization of steatotic liver disease in the setting of immune-mediated inflammatory diseases.
    García-Nieto E; Rodriguez-Duque JC; Rivas-Rivas C; Iruzubieta P; Garcia MJ; Rasines L; Alvarez-Cancelo A; García-Blanco A; Fortea JI; Puente A; Castro B; Cagigal ML; Rueda-Gotor J; Blanco R; Rivero M; Armesto S; González-López MA; Codina AE; Gut M; Vaque JP; Crespo J; Arias-Loste MT
    JHEP Rep; 2024 Oct; 6(10):101167. PubMed ID: 39411649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
    Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
    Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease.
    Chen L; Tao X; Zeng M; Li Y; Han J; Wang Y; Liu Y; Shi R; Su R; Xu L; Mi Y
    J Med Virol; 2024 Apr; 96(4):e29613. PubMed ID: 38634477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
    Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
    Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.